Search

Your search keyword '"Javaheri, Sogol"' showing total 8 results
Start Over Author "Javaheri, Sogol" Publisher elsevier
8 results on '"Javaheri, Sogol"'

2. Contributors

Author

Abbott, Sabra M., primary, Abe, Takashi, additional, Ali, Imran I., additional, Arnedt, J. Todd, additional, Avidan, Alon Y., additional, Bartsch, Ronny P., additional, Benca, Ruth M., additional, Buxton, Orfeu M., additional, Chang, Anne-Marie, additional, Chervin, Ronald D., additional, Collop, Nancy, additional, Corrigan, Jennifer, additional, Dinges, David F., additional, During, Emmanuel H., additional, Dutt, Mohan, additional, Eckert, Danny J., additional, Edinger, Jack D., additional, Eldridge-Smith, E. Devon, additional, Formentin, Chiara, additional, Fuller, Patrick M., additional, Geer, Jacqueline, additional, Goldstein, Cathy, additional, Hanly, Patrick J., additional, Harper, Ronald M., additional, Hirshkowitz, Max, additional, Howell, Michael J., additional, Ip, Mary S.M., additional, Irfan, Muna, additional, Ivanov, Plamen Ch., additional, Javaheri, Shahrokh, additional, Javaheri, Sogol, additional, Jones, Christopher W., additional, Ju, Yo-El S., additional, Kaizi-Lutu, Marc, additional, Kapas, Levente, additional, Kryger, Meir H., additional, Kutscher, Scott J., additional, Lee, Won Y., additional, Liu, Peter Y., additional, Lui, Macy M.S., additional, Lussier, Bethany L., additional, Malhotra, Atul, additional, Malhotra, Raman K., additional, McCall, Catherine A., additional, McCall, William V., additional, Mendelson, Wallace, additional, Montagnese, Sara, additional, Parmeggiani, Pier Luigi, additional, Prather, Aric A., additional, Reid, Kathryn J., additional, Roth, Thomas, additional, Schneider, Logan Douglas, additional, Shapiro, Colin M., additional, Sharafkhaneh, Amir, additional, Sheikh, Ajaz A., additional, Sheldon, Stephen H., additional, Sherman, Deena, additional, Siegel, Jerome M., additional, Spaeth, Andrea M., additional, Stickgold, Robert, additional, Summa, Keith C., additional, Swanson, Leslie, additional, Szentirmai, Éva, additional, Tobias, Lauren, additional, Turek, Fred W., additional, Turnbull, Christopher D., additional, Vaughn, Bradley V., additional, Verrier, Richard L., additional, Wamsley, Erin J., additional, West, Sophie D., additional, Whibley, Daniel, additional, Winkelman, John W., additional, Wojeck, Brian S., additional, Won, Christine H.J., additional, Yao, Steven, additional, Yuen, Kin M., additional, and Zee, Phyllis C., additional

Published
2024
Full Text
View/download PDF

5. Contributors

Author

Allen, Sarah F., primary, Arora, Teresa, additional, Ashare, Rebecca, additional, Barger, Laura K., additional, Baron, Kelly Glazer, additional, Bartel, Kate, additional, Basner, Mathias, additional, Berger, Aaron T., additional, Billings, Martha E., additional, Blanc, Judite, additional, Buxton, Orfeu M., additional, Carskadon, Mary A., additional, Chakravorty, Subhajit, additional, Chang, Anne-Marie, additional, Chaudhary, Ninad S., additional, Chung, Alicia, additional, Culnan, Elizabeth, additional, Dollish, Hannah K., additional, Donley, Tiffany, additional, Ellis, Jason G., additional, Fernandez, Fabian, additional, Fernandez-Mendoza, Julio, additional, Garland, Sheila N., additional, Gaston, Symielle A., additional, Gooneratne, Nalaka S., additional, Grandner, Michael A., additional, Grey, Ian, additional, Gurubhagavatula, Indira, additional, Hale, Lauren, additional, He, Sean, additional, Jackson, Chandra L., additional, James, Sarah, additional, Javaheri, Sogol, additional, Jean-Louis, Girardin, additional, Jobanputra, Aesha M., additional, Johnson, Dayna A., additional, Killgore, William D.S., additional, Kitcher, Andrew, additional, Kline, Christopher E., additional, Kloss, Jacqueline D., additional, Knowlden, Adam P., additional, Lee, Soomi, additional, Li, Junxin, additional, Malhotra, Atul, additional, Malone, Susan Kohl, additional, McCall, Catherine A., additional, McFarlane, Samy I., additional, Meers, Jessica, additional, Mendoza, Maria A., additional, Mondesir, Favel L., additional, Moore, Jesse, additional, Nowakowski, Sara, additional, Nunes, Jao, additional, Omobomi, Omobimpe, additional, Patterson, Freda, additional, Perlis, Michael L., additional, Pitale, Priyamvada M., additional, Popp, Collin, additional, Prather, Aric A., additional, Redline, Susan, additional, Robbins, Rebecca, additional, Rosenberger, Mary E., additional, Saed, Katherine, additional, Satterfield, Brieann C., additional, Seixas, Azizi A., additional, Short, Michelle A., additional, Smith, Isaac, additional, Snyder, Cynthia K., additional, Spaeth, Andrea M., additional, St-Onge, Marie-Pierre, additional, Stout-Aguilar, Jacqueline, additional, Sunwoo, Bernie, additional, Tan, Miranda, additional, Taylor, Brittany V., additional, Thakur, Nina P., additional, Troxel, Wendy M., additional, Tubbs, Andrew S., additional, Vargas, Ivan, additional, Wallace, Douglas M., additional, Watson, Nathaniel F., additional, Weaver, Matthew D., additional, Widome, Rachel, additional, Williams, Natasha, additional, and Xiao, Qian, additional

Published
2019
Full Text
View/download PDF

6. Breathless nights and heart flutters: Understanding the relationship between obstructive sleep apnea and atrial fibrillation.

Author

Mills EW, Antman EM, and Javaheri S

Subjects
Humans, Continuous Positive Airway Pressure, Dyspnea, Risk Factors, Atrial Fibrillation epidemiology, Atrial Fibrillation etiology, Sleep Apnea, Obstructive complications, Sleep Apnea, Obstructive epidemiology, Sleep Apnea, Obstructive therapy
Abstract

There is an extraordinary and increasing global burden of atrial fibrillation (AF) and obstructive sleep apnea (OSA), two conditions that frequently accompany one another and that share underlying risk factors. Whether a causal pathophysiologic relationship connects OSA to the development and/or progression of AF, or whether shared risk factors promote both conditions, is unproven. With increasing recognition of the importance of controlling AF-related risk factors, numerous observational studies now highlight the potential benefits of OSA treatment in AF-related outcomes. Physicians are regularly faced with caring for this important and increasing population of patients despite a paucity of clinical guidance on the topic. Here, we review the clinical epidemiology and pathophysiology of AF and OSA with a focus on key clinical studies and major outstanding questions that should be addressed in future studies., (Copyright © 2023 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

7. Update on Persistent Excessive Daytime Sleepiness in OSA.

Author

Javaheri S and Javaheri S

Subjects
Carbamates, Humans, Modafinil, Phenylalanine analogs & derivatives, Piperidines, Disorders of Excessive Somnolence drug therapy, Disorders of Excessive Somnolence etiology, Sleep Apnea, Obstructive complications, Wakefulness-Promoting Agents therapeutic use
Abstract

OSA is a highly prevalent sleep disorder, and subjective excessive daytime sleepiness (EDS) is the cardinal symptom for which many individuals seek medical advice. Positive airway pressure (PAP) devices, first-line treatment for OSA, eliminates EDS in most patients. However, a subset of patients suffers from persistent EDS despite adherence to therapy. Multiple conditions, some reversible, could account for the residual sleepiness and need to be explored, requiring detailed history, review of PAP data from the smart card, and sometimes additional testing. When all known causes of EDS are excluded, in adequately treated subjects, the purported mechanisms could relate to long-term exposure to the OSA-related sleep fragmentation, sleep deprivation, and hypoxic injury to the arousal system, shifts in melatonin secretion, or altered microbiome. Independent of the mechanism, in well-treated OSA, pharmacological therapy with approved drugs can be considered. Modafinil is commonly prescribed to combat residual EDS, but more recently two drugs, solriamfetol, a dual dopamine-norepinephrine reuptake inhibitor, and pitolisant, a histamine H3 receptor inverse agonist, were approved for EDS. Solriamfetol has undergone randomized controlled trials for treatment of EDS associated with both OSA and narcolepsy, exhibiting robust efficacy. Solriamfetol is renally excreted, with no known drug interactions. Pitolisant, which is nonscheduled, has undergone multiple RCTs in narcolepsy, showing improvement in subjective and objective EDS and one OSA trial showing improvement in subjective EDS., (Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

8. Insomnia and Risk of Cardiovascular Disease.

Author

Javaheri S and Redline S

Subjects
Autonomic Nervous System Diseases etiology, Autonomic Nervous System Diseases mortality, C-Reactive Protein metabolism, Cardiovascular Diseases mortality, Coronary Disease etiology, Coronary Disease mortality, Heart Failure etiology, Heart Failure mortality, Humans, Hypertension etiology, Hypertension mortality, Hypothalamo-Hypophyseal System physiology, Observational Studies as Topic, Pituitary-Adrenal System physiology, Risk Factors, Sleep Initiation and Maintenance Disorders mortality, Cardiovascular Diseases etiology, Sleep Initiation and Maintenance Disorders complications
Abstract

Insomnia is the most prevalent sleep disorder in the United States and has high comorbidity with a number of cardiovascular diseases (CVDs). In the past decade, a number of observational studies have demonstrated an association between insomnia and incident cardiovascular disease (CVD) morbidity and mortality, including hypertension (HTN), coronary heart disease (CHD), and heart failure (HF). Despite some inconsistencies in the literature, likely due to variations in how insomnia is defined and measured, the existing data suggest that insomnia, especially when accompanied by short sleep duration, is associated with increased risk for HTN, CHD and recurrent acute coronary syndrome, and HF. Purported mechanisms likely relate to dysregulation of the hypothalamic-pituitary axis, increased sympathetic nervous system activity, and increased inflammation. This paper reviews the most recent studies of insomnia and CVD and the potential pathophysiological mechanisms underlying this relationship and highlights the need for randomized trials to further elucidate the nature of the relationship between insomnia and CVD., (Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results